Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.
Enumera Molecular has raised $12.5M in total funding. The most recent round was Series A. The last funding was announced in May 2022.
Enumera Molecular's investors include Arboretum Ventures.
Enumera Molecular is headquartered in Ann Arbor, United States.
Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.
Enumera Molecular is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enumera Molecular — Funding & Investors." VCBacked, May 5, 2022, https://www.vcbacked.co/company/enumera-molecular. Accessed November 13, 2026.
VCBacked. (2022). Enumera Molecular — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/enumera-molecular
{{cite web |title=Enumera Molecular — Funding & Investors |url=https://www.vcbacked.co/company/enumera-molecular |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Enumera Molecular? Request a listing update